All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
NICE supports gilteritinib for adults with relapsed/refractory FLT3-mutated AML
The National Institute for Health and Care Excellence (NICE) have released the final appraisal document for the recommendation of gilteritinib, a highly selective, second generation FLT3 inhibitor for adults with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), making it the first oral monotherapy to be approved in the United Kingdom for this patient population. However, the recommendation does not extend to maintenance use after hematopoietic stem cell transplant.1
This recommendation is based on results from the phase III ADMIRAL trial (NCT02421939), which demonstrated a significantly longer median overall survival (9.3 vs 5.6 months; p < 0.001) and deeper responses for patients treated with gilteritinib compared with salvage chemotherapy, respectively. One-year overall survival was also higher for patients treated with gilteritinib compared with salvage chemotherapy (37.1% vs 16.7%, respectively; HR 0.64; 95% CI, 0.49–0.83). For more information on the results from this trial, read our summary article here.
Gilteritinib has already received approval as a single agent from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), based on results from the same trial.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?